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Introduction: Triplications of SNCA, the gene encoding for a-synuclein, cause a very rare Mendelian form
of early-onset parkinsonism combined with cognitive and autonomic dysfunctions. Only six families with
SNCA triplications have been described so far, limiting our knowledge of the associated phenotype. In this
study, we report clinical and genetic ﬁndings in a new Italian family with SNCA triplication.
Methods: The patients' phenotype was assessed by neurological examination, neuropsychological tests,
and brain imaging (MRI and SPECT-DaTSCAN). For the genetic investigation, we used three independent
techniques: genome-wide SNP microarrays, ﬂuorescence in situ hybridization (FISH), and multiplex
ligation-dependent probe ampliﬁcation (MLPA).
Results: Genetic studies documented the presence of four copies of the SNCA gene in the affected family
members. FISH experiments and the segregation in the family were consistent with a heterozygous
triplication of the SNCA locus. The patients carrying the SNCA triplication developed early-onset
parkinsonism combined with depression, behavior disturbances, sleep disorders, and cognitive
decline; marked autonomic dysfunctions were not observed. Brain imaging revealed fronto-parietal
atrophy and a severe striatal dopaminergic deﬁcit.
Conclusion: The identiﬁcation of this novel family contributes to the genetic and clinical characterization
of this rare form. Our data reinforce the view that SNCA triplications cause early-onset parkinsonism,
with prominent non-motor features.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Genetic studies of the familial forms of Parkinson's disease (PD)
have led to the identiﬁcation of disease-causing mutations in six
genes: SNCA, LRRK2, VPS35, Parkin, PINK1, and DJ-1 [1]. The ﬁrst to
be discovered was the gene encoding for a-synuclein, SNCA.
The pathogenic role of SNCA mutations was ﬁrst identiﬁed
through the study of large families with autosomal dominant PD
from Italy and Greece [2]. Subsequent studies identiﬁed additional
pathogenic mutations, including missense mutations andnetics, Erasmus MC, PO Box
ati).multiplications (duplications and triplications) [3,4]. While SNCA
duplications are relatively common in familial PD cases (1.5% in
autosomal dominant PD), missense mutations and triplications are
extremely rare [4].
To our knowledge, SNCA triplications have been reported in only
four extended families [3e6] and two single patients [7,8]. The
patients reported so far developed an aggressive form of early-
onset parkinsonism, combined with additional non-motor signs,
such as cognitive and autonomic dysfunctions. These clinical pre-
sentations support the idea that SNCA triplications cause a more
severe phenotype than SNCA duplications, consistently with the
underlying genetic defects (i.e., triplications result in one more
copy of the SNCA gene than duplications). Nevertheless, since the
number of reported families is limited, more data are required to
derive any solid conclusions.
S. Olgiati et al. / Parkinsonism and Related Disorders 21 (2015) 981e986982Here, we report the identiﬁcation of a triplication at the SNCA
locus in a new family from the Abruzzi region, Italy. We provide
clinical descriptions, instrumental evaluations, and videos of the
affected family members, and we use three independent tech-
niques to support our genetic ﬁndings.
2. Methods
We performed clinical and genetic studies on a family from the
Italian region of Abruzzi. The four-generation pedigree of the family
is provided in Fig. 1A. This study was approved by the appropriate
institutional review boards and all participants provided written
informed consent.
Genomic DNAwas isolated from peripheral blood with standard
protocols. We performed gene dosage of SNCA, parkin, PINK1, DJ-1,
GCH1, and ATP13A2 using multiplex ligation-dependent probe
ampliﬁcation (MLPA) kits P051 and P052 (MRC Holland, Amster-
dam, The Netherlands) in all the participating family members.
MLPA experiments were conducted following the manufacturer's
protocols.
In order to conﬁrm the aberrant number of copies at the SNCA
locus, we employed two additional techniques. First, we performed
a copy-number variant analysis of the SNCA locus in the index case
IV-6 using Illumina HumanOmniExpress BeadChip array (Illumina,
San Diego, California; 730,525 SNPs at a median distance of 2.1 kb).
The data were analyzed using Nexus Copy Number, Discovery
Edition, Version 7 (BioDiscovery, El Segundo, California). Second,
Fluorescence in situ hybridization (FISH) was carried out on blood
mononuclear cells of subject IV-6. Bacterial artiﬁcial chromosome
(BAC) DNA clones (RP11-502A23, RP11-115D19, RP11-188M16, and
RP11-252C9) were labeled using BioPrime DNA Labeling System
(Life Technologies, Carlsbad,California) with either digoxigenin-11-
dUTP (Roche, Basel, Switzerland), biotin-16-dUTP (Roche, Basel,
Switzerland), or cyanine 3-dCTP (Perkin Elmer, Waltham, Massa-
chusetts). For the ﬁrst two labelling methods, probes were detected
using anti-digoxigenin FITC (Roche, Basel, Switzerland) or Strep-
tavidin Alexa 594 (Life Technologies, Carlsbad,California). The FISH
experiments were performed according to standard protocols.
Genomic locations of the probes were retrieved from NCBI Clone
DB, or using eFISH (http://projects.tcag.ca/cgi-bin/eﬁsh/index.cgi).
3. Results
3.1. Case reports
The index patient (IV-6) developed the ﬁrst symptoms of the
disease in 2003, at the age of 28 years (Table 1). At that time, he
presented facial hypomimia, rigidity, and bradykinesia more
prominent on the left side; depression and REM sleep behavior
disorder were also present. His Hoehn/Yahr stage was 2, and his
UPDRS III score was 7. Brain MRI revealed bilateral fronto-parietal
atrophy, while SPECT-DaTSCAN (Suppl. Fig. A) showed reduced
tracer binding in the caudate nuclei and in the putamen (more
prominent to the right). The binding reduction was more severe
than the reduction usually observed in early stage PD, especially in
the caudate nuclei. After a year, despite the treatment with
dopamine agonist, the UPDRS III score increased to 15 and L-Dopa
was introduced in the therapy (400 mg/day). In the following
years, the patient developed hypersexuality, delirium of jealousy,
and aggressive behavior. The therapy was modiﬁed removing the
dopamine agonist and adding clozapine (50 mg/day). In 2012
(Video1), the Hoehn/Yahr stage was 3.5, the UPDRS III score was
40, and cognitive testing showed a deﬁcit in the executive func-
tions, cognitive ﬂexibility, and planning (mini-mental state ex-
amination 23/30, frontal assessment battery 5/18, dementia ratingscale-2 112). At our last examination in 2014, after disease dura-
tion of 11 years, Hoehn/Yahr stage was 4, UPDRS III score was 63,
and therapy consisted of L-Dopa in combination with atypical
antipsychotics.
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.parkreldis.2015.06.005.
The patient's sister (IV-5) developed the symptoms of the dis-
ease later than her brother, at 42 years old (Table 1). At ﬁrst ex-
amination, she had facial hypomimia, rigidity, and bradykinesia
more prominent on the right side (Video 2). She also reported REM
sleep behavior disorder since adolescence, depressive episodes
during the last ﬁve years, and three spontaneous abortions in the
second trimester of pregnancy from 2010 to 2012. Her Hoehn/Yahr
stage was 2 and UPDRS III score was 9. She refused to receive
therapy for her motor symptoms. Neuropsychological tests were
within normal limits. MRI was normal, while SPECT-DaTSCAN
showed bilateral reduced binding in the putamen (left
side> right side) and no signiﬁcant alterations in the caudate nuclei
(Suppl. Fig. B).
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.parkreldis.2015.06.005.
Information about the family historywas reported by subject IV-
5 and also documented, in part, by hospital records. The pattern of
inheritance was compatible with a Mendelian autosomal dominant
trait (Fig. 1A). The mother (III-4) of IV-5 and IV-6 developed PD at
the age of 30. Her clinical signs included rigidity, bradykinesia and
tremor of the left hand. From the onset of the disease, she also
suffered from depression and anxiety. Her treatment consisted in
biperiden, L-Dopa, and benzodiazepines. She died at the age of 43
years old, after disease duration of 13 years; her last hospital re-
cords reported cognitive decline, psychomotor agitation, and se-
vere behavior disturbances.
Only few information were available for the previous genera-
tions. The maternal grandmother of the index case (II-4) was re-
ported with early-onset PD, and died at 45 years old by unknown
causes. The grandmother's sister (II-2) was reported with symp-
toms of PD at the age of 55 and died at the age of 72. The maternal
grand grandmother (I-2) had symptoms compatible with PD and
died at the age 40 by unknown causes.
3.2. Genetic results
The MLPA experiments identiﬁed an aberrant number of copies
of SNCA in the two affected siblings (IV-5 and IV-6). The signal in-
tensity for all the SNCA probes included in theMLPA kits (exons 2, 3,
4, 5, 6, and 7) was double than expected in a diploid genome,
supporting the existence of four copies of the gene (Fig. 1B and C).
This abnormal copy number was not detected in any other family
members (Fig.1A). Our copy-number analysis using SNP arrays data
conﬁrmed the copy-number gain in the chromosomal region
4q22.1. The analysis showed both an increased Log R ratio and a
deviation from the expected values of the B-allele frequency
(Fig. 1D), two abnormalities that support increased gene dosage
and deviation from diploidy. The centromeric border of the tripli-
cation was predicted between rs13148714 and rs12649385, while
the telomeric side was between rs1903577 and rs7688033: a region
with maximum size of 1.30 Mb. The analysis of this genomic region
using the UCSC Genome Browser revealed the presence of ﬁve
protein-coding genes: TIGD2, GPRIN3, SNCA, MMRN1, and CCSER1.
To further investigate this genomic rearrangement, we per-
formed FISH experiments in blood cells of subject IV-6 using four
different probes that annealed within, or just outside the genomic
region indicated by our copy-number analysis (Fig. 1D). Represen-
tative results are provided in Fig. 1E and F. The probes annealing
outside the region yielded two signals, while the probes annealing
Fig. 1. Genetic ﬁndings in a family with SNCA triplication. AdPedigree of the Italian family with SNCA triplication. To protect subjects' privacy, the gender of some subjects has been
disguised. mut, SNCA triplication; wt, wild type (normal number of SNCA copies). B,CdMLPA experiments in subject IV-6 support the presence of four copies of SNCA. Gene dosage is
expressed as Peak Ratio (vertical axes): the ratio between measured signal and a control sample. A Peak Ratio of one corresponds to a gene dosage of two copies, while a Peak Ratio
of two corresponds to a gene dosage of four copies. Squares represent the results of the MLPA probes; SNCA probes are depicted in red; probes of additional genes are depicted in
green; white squares represent the probes detecting point mutations. DdCopy-number variant analysis of chromosome 4 using SNP arrays data from subject IV-6. Log R ratio and B-
allele frequency (vertical axes) are represented as a function of the genomic position (horizontal axis). Blue and purple boxes indicate the triplicated region. Black arrows indicate
the positions of the ﬁve genes involved in the triplication; green, red, and orange rectangles display the position of the FISH probes. E,FdRepresentative results of the FISH ex-
periments supporting the increased dosage of the SNCA gene. Control probes are labeled in green, and display two signals, while the probes within the triplicated region are labelled
in orange or red, and display four signals. Also, the clustering of the signals suggests that three copies of SNCA are on the same chromosome, supporting a heterozygous triplication.
Green (panel D) RP11-252C9; green (panel E) RP11-502A23; orange RP11-188M16; red RP11-115D19.
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Table 1
Clinical and genetic features of patients with SNCA triplications.
Reference This study Waters et al., 1994; Muenter et al., 1998;
Singleton et al., 2003;
Ross et al., 2008; Gwinn et al., 2011
Farrer et al., 2004;
Fuchs et al., 2007;
Ross et al., 2008
Ibanez et al., 2009 Sekine et al., 2010 Keyser et al., 2010 Byers et al., 2011
Subject ID IV-5 IV-6 III-4 14 affected Relatives 4 affected Relatives 3 affected Relatives 3 affected Relatives 1 familial PD
patient
1 PD patient
Gender F M F 6 M, 8 F 2 M, 2 F 2 M, 1 F 3 M M M
Genotyped individuals Yes Yes No 4 1 1 1 1 1
Size of the triplicated
region (Mb)
1.29 to 1.30 1.69 to 1.83 0.82 to 0.84 2.61 to 2.64 >0.40 N/A N/A
Genes in triplication TIGD2, GPRIN3, SNCA, MMRN1, CCSER1 HERC6, HERC5, PIGY, PYURF, HERC3,
NAP1L5, FAM13A, TIGD2,
GPRIN3, SNCA, MMRN1, CCSER1
SNCA, MMRN1,
CCSER1
GPRIN3, SNCA,
MMRN1,
CCSER1
SNCA, MMRN1,
CCSER1
SNCA SNCA
Onset age (y.rs) 42 28 30 24e48 (range) 31 36e61 (range) 28e49 (range) 46 38
Disease duration (y.rs) 2 11 13 ~8 (average) 21 5e10 (range) 3e8 (range) 9 2
Rigidity þ þ þ þ þ 3/3 3/3 þ þ
Bradykinesia þ þ þ þ þ 3/3 3/3 þ þ
Rest tremor þ e þ þ þ 2/3 3/3 þ þ
Response to L-Dopa N/A þ þ þ (initially) þ 3/3 3/3 þ þ
Motor ﬂuctuations e e N/A þ þ N/A N/A N/A þ
REM sleep behavior disorder þ þ N/A þ þ N/A 0/3 N/A þ
Orthostatic hypotension e e e þ þ N/A 3/3 þ e
Urinary incontinence e e N/A þ þ 3/3 0/3 N/A e
Depression þ þ þ þ þ N/A 2/3 N/A þ
Cognitive decline e þ þ þ þ 2/2 2/3 þ þ
Psychotic disturbances e þ þ þ þ N/A 2/3 þ e
F, female; M, male; þ, present; -, absent; N/A, not available.
Byers B et al., PLoS One 2011; 6:e26159. Farrer M et al., Ann Neurol 2004; 55:174e9. Fuchs J et al., Neurology 2007; 68:916e22. Gwinn K et al., Mov Disord 2011; 26:2134e6. Ibanez P et al., Arch Neurol 2009; 66:102e8. Keyser RJ
et al., Neurogenetics 2010; 11:305e12. Muenter et al., Ann Neurol 1998; 43:768e81. Ross OA et al., Ann Neurol 2008; 63:743e50. Sekine T et al., Mov Disord 2010; 25:2871e5. Singleton AB et al., Science 2003; 302:841. Waters
CH et al., Ann Neurol 1994; 35:59e64.
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the four signals in the nuclei was consistent with having three
copies of SNCA on one chromosome and one copy on the other
chromosome.
4. Discussion
Here, we report on the identiﬁcation of a novel family with
early-onset parkinsonism and triplication of the SNCA gene. The
existence of four copies of the SNCA gene was consistently detected
using three different genetic techniques, and the mutation segre-
gated with the disease in the two patients with early-onset PD
available for testing, while unaffected subjects did not carry this
mutation. The pattern of familial transmission of the disease, the
presence of a normal number of copies of the SNCA gene in the
unaffected father (III-3), and the results of the FISH experiments
support the contention that the aberrant number of copies is the
result of a heterozygous triplication, rather than a homozygous
duplication. Of note, subject II-2 did not carry the mutation. The
clinical data available for this patient are very limited, but she
developed the disease later than the rest of the affected family
members and had prolonged disease duration. For these reasons,
we consider her as a phenocopy.
As SNCA triplications are very rare, the clinical description of
such families is valuable. The affected family members developed
an early-onset form of parkinsonism combined with sleep disor-
ders, cognitive decline, and behavioral disturbances. Brain imaging
revealed fronto-parietal atrophy in one of the affected siblings, and
a severe dopaminergic deﬁcit at the level of the caudate nuclei and
putamen. Unlike the cases previously reported, these new patients
with SNCA triplication did not suffer from severe, symptomatic
autonomic dysfunctions such as urinary incontinence, or postural
hypotension, and did not experience visual, or auditory hallucina-
tions. Nevertheless, the presentation, progression, and onset age of
the disease in this novel family support the notion that SNCA
triplication causes early-onset parkinsonism with additional
prominent non-motor signs. This phenotype is more severe than
the phenotype of patients with SNCA duplication, which may
resemble idiopathic PD [9]. Recently, the combination of data from
multiple families [3,4,10] was used to propose an explanation for
the phenotypic differences between SNCA duplications and tripli-
cations. These studies suggested that, rather than affecting the
severity of the disease, the different gene dosage can modify the
penetrance and variability of the phenotype, with triplications
causing fully-penetrant forms with earlier onset and prominent
non-motor features. Our new family adds new data and reinforces
this notion.
Few studies have shed light on the effects of these mutations.
Triplications of the SNCA gene are known to increase a-synuclein
protein levels in the blood and in postmortem brain tissue [11].
Also, increased expression and accumulation of a-synuclein have
been observed in midbrain dopaminergic neurons differentiated
from induced pluripotent stem (iPS) cells with SNCA triplications
[8,12]. These studies demonstrate that the gene dosage of SNCA can
modify the expression levels of the corresponding protein.
Not all the SNCA triplications described so far are of the same
size or involve the same genes, but the comparison of the different
triplications reported is made difﬁcult by incompleteness of the
data. If we consider the three families with available detailed in-
formation, the triplication in two families [3,4] extends to a bigger
genomic region than in our family, while the genomic region in the
third family [5] is smaller than in the novel family. Also, like in the
previous families, SNCA is not the only gene altered by the muta-
tion, and the other genes involved might act as modiﬁers, thereby
possibly explaining part of the variability of the phenotype.The identiﬁcation of a novel family with SNCA triplication is an
important step towards a better characterization of the phenotype
associated with this very rare Mendelian form of parkinsonism.
Despite the rarity of triplications at the SNCA locus, duplications are
relatively common (1.5% in autosomal dominant PD [4]), and
diagnostic laboratories should consider testing the SNCA copy
number in patients with autosomal dominant PD.
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